Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3249]

$ASH 2013: Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies following T cell immunotherapy$

ASH 2013: Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell...

ASH 2013: Immune reconstitution and preliminary safety analysis of somatic gene therapy for immunodeficiency

ASH 2013: Immune reconstitution and preliminary safety analysis of somatic gene therapy for immunodeficiency

ASH 2013: Removal of alpha/beta T cells and of CD19 B cells in children with acute leukaemia

ASH 2013: Removal of alpha/beta T cells and of CD19 B cells in children with acute leukaemia

Scientists fingerprint single cancer cells to map cancer’s family tree

Scientists fingerprint single cancer cells to map cancer’s family tree

FDA gives accelerated approval to ibrutinib for mantle cell lymphoma

FDA gives accelerated approval to ibrutinib for mantle cell lymphoma

COSA: Thalidomide fails to help patients with malignant pleural mesothelioma

COSA: Thalidomide fails to help patients with malignant pleural mesothelioma

NCRI 2013: Redirecting our immune cells to help fight children's cancer

NCRI 2013: Redirecting our immune cells to help fight children's cancer

Highlights from day three, afternoon session, of the 2013 NCRI Cancer Conference

Highlights from day three, afternoon session, of the 2013 NCRI Cancer Conference

FDA approves obinutuzumab for chronic lymphocytic leukaemia

FDA approves obinutuzumab for chronic lymphocytic leukaemia

FDA pulls ponatinib approval due to blood clots and narrowing of blood vessels

FDA pulls ponatinib approval due to blood clots and narrowing of blood vessels

More from ecancer